• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

天然存在的糖蛋白41 HR1变异对HIV-1对融合抑制剂敏感性的影响。

Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors.

作者信息

Chinnadurai Raghavan, Münch Jan, Kirchhoff Frank

机构信息

Department of Virology, Universitätsklinikum, Ulm, Germany.

出版信息

AIDS. 2005 Sep 2;19(13):1401-5. doi: 10.1097/01.aids.0000180785.25800.de.

DOI:10.1097/01.aids.0000180785.25800.de
PMID:16103771
Abstract

BACKGROUND

Sequence variations in the gp41 heptad repeat 1 (HR1) region have been identified in some treatment-naive HIV-1-infected patients but it remained elusive whether they confer resistance to fusion inhibitors.

OBJECTIVE

To evaluate whether naturally occurring sequence variations in the HIV-1 group M gp41 HR1 region affect the sensitivity to inhibition by T-20 and T-1249.

METHODS

Site-directed mutagenesis was used to generate HIV-1 NL4-3 mutants containing changes in the gp41 HR1 domain which have been previously identified in treatment-naive patients infected with various HIV-1 group M subtypes. HIV-1 variants were produced by transient transfection of 293T cells and used to determine viral infectivity and sensitivity to the fusion inhibitors T-20 and T-1249.

RESULTS

Most naturally occurring sequence variations in the HR1 domain did not reduce viral infectivity. Three of the 10 HIV-1 variants analysed containing a single substitution of L33V, which is frequently present in subtype D isolates, or combined changes of L54M/Q56K or L34M/L54M/Q56R showed about fivefold reduced sensitivity to inhibition by T-20. In comparison, none of these HR1 sequence variations conferred resistance to T-1249.

CONCLUSION

Some naturally occurring sequence variations in the gp41 HR1 region reduce sensitivity of HIV-1 to inhibition by T-20 but not T-1249.

摘要

背景

在一些未经治疗的HIV-1感染患者中已发现gp41七肽重复序列1(HR1)区域存在序列变异,但这些变异是否赋予对融合抑制剂的耐药性仍不明确。

目的

评估HIV-1 M组gp41 HR1区域自然发生的序列变异是否会影响对T-20和T-1249抑制的敏感性。

方法

采用定点诱变技术构建HIV-1 NL4-3突变体,其gp41 HR1结构域发生了先前在感染各种HIV-1 M组亚型的未经治疗患者中鉴定出的变化。通过瞬时转染293T细胞产生HIV-1变体,并用于测定病毒感染性以及对融合抑制剂T-20和T-1249的敏感性。

结果

HR1结构域中大多数自然发生的序列变异并未降低病毒感染性。分析的10个HIV-1变体中有3个含有L33V单一位点替换(常见于D亚型分离株),或L54M/Q56K或L34M/L54M/Q56R的联合变化,这些变体对T-20抑制的敏感性降低了约5倍。相比之下,这些HR1序列变异均未赋予对T-1249的耐药性。

结论

gp41 HR1区域中一些自然发生的序列变异会降低HIV-1对T-20抑制的敏感性,但不会降低对T-1249抑制的敏感性。

相似文献

1
Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors.天然存在的糖蛋白41 HR1变异对HIV-1对融合抑制剂敏感性的影响。
AIDS. 2005 Sep 2;19(13):1401-5. doi: 10.1097/01.aids.0000180785.25800.de.
2
Amino acid conservation in the gp41 transmembrane protein and natural polymorphisms associated with enfuvirtide resistance across HIV-1 variants.HIV-1各变体中gp41跨膜蛋白的氨基酸保守性及与恩夫韦肽耐药性相关的自然多态性。
AIDS Res Hum Retroviruses. 2007 Sep;23(9):1067-74. doi: 10.1089/aid.2006.0256.
3
Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.七肽重复序列2突变增强了对恩夫韦肽耐药的HIV-1 gp41发夹结构的稳定性。
Antivir Ther. 2005;10(8):893-900.
4
Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.HIV-1 env 基因区 HR1-HR2 以外区域对融合抑制剂恩夫韦肽耐药性和临床分离株病毒感染力的影响。
PLoS One. 2011;6(7):e21535. doi: 10.1371/journal.pone.0021535. Epub 2011 Jul 8.
5
Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides.1型人类免疫缺陷病毒对膜锚定的gp41衍生肽耐药性的决定因素。
J Virol. 2005 Aug;79(16):10237-46. doi: 10.1128/JVI.79.16.10237-10246.2005.
6
Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.包膜基因背景在1型人类免疫缺陷病毒感染患者中恩夫韦肽耐药性发展中的作用。
J Virol. 2006 Sep;80(17):8807-19. doi: 10.1128/JVI.02706-05.
7
Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART.来自巴西接受高效抗逆转录病毒治疗(HAART)失败患者的1型艾滋病毒B、C和F亚型分离株中的恩夫韦肽(T - 20)耐药相关突变。
AIDS Res Hum Retroviruses. 2009 Feb;25(2):193-8. doi: 10.1089/aid.2008.0160.
8
Human immunodeficiency virus type 1 gp 41 mutations in proviral DNA among antiretroviral treatment-naive individuals from India.来自印度的未接受过抗逆转录病毒治疗个体的前病毒DNA中1型人类免疫缺陷病毒gp 41突变
AIDS Res Hum Retroviruses. 2009 May;25(5):521-3. doi: 10.1089/aid.2008.0244.
9
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.在恩夫韦肽治疗期间选择的1型人类免疫缺陷病毒gp41氨基酸取代对恩夫韦肽体外gp41结合及抗病毒效力的影响
J Virol. 2005 Oct;79(19):12447-54. doi: 10.1128/JVI.79.19.12447-12454.2005.
10
Mutation L33M in the HR1 region of HIV-1 gp41 may play a role in T20 resistance.HIV-1 gp41的HR1区域中的L33M突变可能在T20耐药性中起作用。
J Clin Virol. 2009 Jul;45(3):255-8. doi: 10.1016/j.jcv.2009.05.001. Epub 2009 May 31.

引用本文的文献

1
Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique.来自莫桑比克马普托市的HIV-1 gp41分离株的基因分析及自然多态性
AIDS Res Hum Retroviruses. 2014 Jun;30(6):603-9. doi: 10.1089/aid.2013.0244. Epub 2013 Dec 21.
2
Structural basis of potent and broad HIV-1 fusion inhibitor CP32M.强效广谱 HIV-1 融合抑制剂 CP32M 的结构基础。
J Biol Chem. 2012 Aug 3;287(32):26618-29. doi: 10.1074/jbc.M112.381079. Epub 2012 Jun 7.
3
Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.
3-马来酰亚胺基丙基磺酸酯修饰的肽融合抑制剂 albuvirtide 的生物物理特性和广谱抗 HIV 活性。
PLoS One. 2012;7(3):e32599. doi: 10.1371/journal.pone.0032599. Epub 2012 Mar 5.
4
Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.广谱抗病毒活性和 HIV-1 融合抑制剂西夫韦肽的晶体结构。
J Biol Chem. 2012 Feb 24;287(9):6788-96. doi: 10.1074/jbc.M111.317883. Epub 2012 Jan 6.
5
Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.对HIV-1对三代融合抑制剂敏感性的详细机制洞察。
J Biol Chem. 2009 Sep 25;284(39):26941-50. doi: 10.1074/jbc.M109.004416. Epub 2009 Jul 17.
6
Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.对第一代和第二代融合抑制剂耐药且在体外人淋巴组织中具有细胞病变效应的1型人类免疫缺陷病毒变体。
J Virol. 2007 Jun;81(12):6563-72. doi: 10.1128/JVI.02546-06. Epub 2007 Apr 11.